BioSight
Companies
ImmunityBio, Inc. logo

IBRX

NASDAQSAN DIEGO, CA
ImmunityBio, Inc.

ImmunityBio develops immunotherapy treatments designed to restore immune function in cancer patients by reversing lymphopenia, the loss of functional immune cells caused by cancer and cancer treatments like chemotherapy and radiation. The company's lead product, ANKTIVA, is an IL-15 receptor superagonist complex that has achieved regulatory approval. ImmunityBio is in late-stage clinical development with approved and investigational cancer immunotherapy candidates.

Price history not yet available for IBRX.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar